MedTrace Logo

Analgesics in the Pre-hospital Setting: Implications on Hemorrhage Tolerance - Sufentanil

NCT04959812 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-06-26

Study results available
· View outcomes & findings →

Summary

This study will examine how sufentanil (a commonly used pain medication) will alter responses to simulated blood loss in humans. To simulate blood loss in the research laboratory, participants will complete a test with their lower body in a custom-designed vacuum chamber for a brief period of time.

Conditions

  • Healthy

Interventions

DRUG

Sufentanil

Subjects will receive Sufentanil while the effects of this drug on tolerance to a hemorrhagic insult will be assessed.

OTHER

Placebo

Subjects will receive a placebo pill while the effects of this placebo on tolerance to a hemorrhagic insult will be assessed.

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-09-08
Completion
2023-09-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04959812 on ClinicalTrials.gov